Psilocin is the compound directly responsible for the psychoactive effects of “magic mushrooms.” When you consume psilocybin (the substance found in the mushrooms themselves), your body rapidly converts it into psilocin, which then binds to serotonin receptors in the brain and triggers a cascade of neurological changes. Psilocin is roughly 1.4 times as potent as psilocybin, a ratio that matches the molecular weight difference between the two compounds.
How Psilocybin Becomes Psilocin
Psilocybin is a prodrug, meaning it’s biologically inactive until your body processes it. An enzyme called alkaline phosphatase strips a phosphate group from the psilocybin molecule, converting it into psilocin. This happens quickly after ingestion, primarily in the gut and liver. Psilocin levels in the blood typically peak about 2 to 3 hours after an oral dose, though the range across studies spans roughly 1.75 to 4 hours depending on the individual and the dose.
Once circulating, psilocin has an elimination half-life of approximately 2 to 5 hours. That means the subjective effects generally last 4 to 6 hours total, with the most intense period concentrated around the peak plasma levels. After that, the body breaks psilocin down further and clears it through the kidneys.
Binding to Serotonin Receptors
Psilocin’s primary action is mimicking serotonin, one of the brain’s key chemical messengers. It binds with similar strength to three important serotonin receptor types: the 5-HT2A receptor, the 5-HT2C receptor, and the 5-HT1A receptor. Binding affinities across these three receptors fall in a comparable range (roughly 80 to 310 nM), which means psilocin doesn’t strongly favor one over another.
The 5-HT2A receptor is the most important for psilocin’s psychoactive effects. When psilocin activates this receptor on a specific type of brain cell called layer 5 pyramidal neurons, it amplifies their excitatory signaling. This triggers a downstream release of glutamate, the brain’s primary excitatory neurotransmitter, particularly in the prefrontal cortex and hippocampus. The glutamate surge, in turn, activates inhibitory cells that release GABA, creating a complex push-and-pull dynamic across neural circuits. This interplay between excitation and inhibition is central to the altered states of consciousness psilocin produces.
Rewiring Brain Network Communication
One of psilocin’s most striking effects is how it reshapes the way brain networks talk to each other. Under normal conditions, the brain operates in a modular fashion: distinct networks handle distinct tasks, and they stay relatively segregated. Psilocin disrupts this pattern in a specific, measurable way.
The default mode network (DMN), a set of brain regions active during self-reflection, mind-wandering, and maintaining your sense of identity, shows a robust decrease in internal connectivity as psilocin blood levels rise. The key hubs of this network, located in the medial prefrontal cortex and the posterior cingulate cortex, become decoupled from each other. At the same time, connectivity between the DMN and other brain networks increases. The brain shifts from its usual segregated state to a more globally interconnected one.
This decoupling of the DMN is closely linked to the subjective experience of “ego dissolution,” the feeling that boundaries between self and environment are dissolving. The reduced DMN integration has been observed to persist for up to three weeks after a single dose in people with depression, suggesting these network-level changes outlast the acute drug effects.
Visual Effects and Sensory Changes
The vivid visual distortions people report under psilocin, from geometric patterns to complex imagery with closed eyes, arise from a shift in how the brain processes visual information. Psilocin reduces the strength of “feedforward” signals traveling from the eyes through the primary visual pathway. At the same time, it enhances “feedback” signals flowing from higher-order brain areas back down into early visual regions. The result is that internal mental imagery and associations begin to override or blend with actual sensory input.
With eyes closed, this effect is especially pronounced. The normal inhibitory mechanisms that keep the visual system quiet when there’s nothing to see get disrupted. Activity patterns resembling real visual input appear in the visual cortex, driven by top-down signals from associative brain regions. The process resembles what happens during dreaming: the brain generates vivid imagery from its own internal models rather than from external light hitting the retina.
Synesthesia, where one sense bleeds into another (such as “seeing” music), is common under psilocin. This likely reflects the same breakdown of signal boundaries. When the usual walls between sensory processing streams weaken, associative brain areas can project their activity into the visual system, creating imagery triggered by sound, touch, or emotion.
Promoting New Neural Connections
Beyond its acute effects, psilocin triggers longer-lasting changes in brain cells that fall under the umbrella of neuroplasticity. In human cortical neurons grown in the lab, psilocin increased the production of BDNF, a protein that supports the growth and survival of neurons. This effect was mediated through the 5-HT2A receptor, confirming it’s driven by the same binding that produces psilocin’s psychoactive effects.
Genetic analysis of these neurons revealed that psilocin activates gene expression programs associated with axonal growth, synaptic remodeling, learning, memory, and cognition. These changes appeared within one day and were still detectable three days after exposure. On a structural level, neurons exposed to psilocin showed greater complexity, with more branching, and increased levels of synaptic proteins, particularly in the postsynaptic compartment where signals are received. In practical terms, psilocin appears to prime brain cells to form and strengthen new connections, which may explain why therapeutic benefits in clinical trials often persist weeks or months after a single session.
Physical Effects on the Body
Psilocin’s effects aren’t limited to the brain. It produces measurable changes in heart rate and blood pressure that are transient and dose-dependent. At moderate to high doses (equivalent to 20 to 30 mg of psilocybin), systolic blood pressure typically rises to around 138 to 155 mmHg from a baseline of roughly 112 to 125 mmHg. Heart rate increases modestly, peaking at about 82 to 94 beats per minute compared to resting values of 68 to 78. Pupil dilation is also common.
These cardiovascular effects peak roughly 1.5 to 2 hours after ingestion and resolve within 4 to 6 hours. Across clinical studies, the increases have been described as transient and have not required medical intervention. That said, the blood pressure spikes can push some individuals into the range of systolic hypertension (above 140 mmHg), which is relevant for anyone with pre-existing cardiovascular conditions.
Toxicity Profile
Psilocin has a wide safety margin relative to its active dose. In mice, the LD50 (the dose lethal to 50% of test animals) for pure psilocin is approximately 293 mg/kg of body weight. To put that in rough perspective, the psychoactive dose used in human clinical trials is typically 0.2 to 0.4 mg/kg, making the lethal dose in animals hundreds of times higher than what produces psychological effects. No human fatalities from psilocin toxicity alone have been documented in clinical settings. At very high doses in animal studies (above 200 mg/kg), researchers observed initial hyperactivity followed by decreased movement and disrupted reflexes, but these doses are far beyond anything encountered in typical use.